Development, Qualification, or Validation?

Part 1 of the PCR Assay Validation Guide — Understanding the qPCR/dPCR Assay Lifecycle

Validation is a critical part of generating reliable bioanalytical data. Through this guide, we aim to provide a practical overview of how qPCR and dPCR assays are developed, qualified, and validated in regulated bioanalysis, and how the level of validation should be aligned with the intended use of the data.

In pre-clinical and clinical drug development, assay results are frequently used to support decisions on safety, efficacy, pharmacokinetics, biodistribution, and biomarker performance. The confidence placed in those decisions depends on confidence in the analytical method itself. Understanding how to appropriately develop, qualify, and validate an assay is therefore essential for generating robust and reproducible data.

In this opening post, we introduce the key differences between assay development, qualification, and validation, explain why context of use should be the starting point for every validation strategy, and discuss extraction efficiency and recovery — two important components of method validation.

Start With Context of Use

The key question is not simply whether the assay works, but what decision the data will support. Context of use determines the evidence needed to demonstrate that the assay is fit for purpose and capable of supporting that decision with confidence. It influences:

• The choice of matrix and reference material
• The calibration and quality control strategy
• The validation parameters that must be assessed
• The acceptance criteria that must be met
• The overall scope of the validation effort

Development, Qualification and Validation: Three Different Questions

Development, qualification, and validation each serve a distinct purpose within the lifecycle of a bioanalytical assay.

Development asks: will the assay work, how well does it work, and how can it be optimised? This is where primer/probe design, amplicon confirmation, reverse transcription conditions, extraction strategy, assay efficiency, early sensitivity and robustness are explored.

Qualification asks: is the assay good enough for this specific purpose right now? It is usually a lighter, fit-for-purpose assessment of performance, using a reduced set of experiments and documentation compared with full validation. Qualification can be appropriate for feasibility work, exploratory biomarker analysis, method comparison, internal decision-making or early programme support, depending on how the data will be used.

Validation asks: does the locked method meet predefined criteria, with documented evidence supporting its consistent performance? Validation is the formal package required when the data will support regulatory, pivotal, safety, efficacy or pharmacokinetic conclusions. In that setting, development or qualification data alone are not enough; the method must be prospectively planned, appropriately documented and justified against its context of use.

What Happens During Development

A typical qPCR/dPCR development phase may include:

• Method development including extraction optimisation and evaluation of efficiency and recovery
• Feasibility testing and primer/probe evaluation
• Amplicon confirmation and reverse transcription evaluation for RNA targets
• Analysis of representative context samples
• Early assessment of selectivity, specificity, sensitivity, PCR efficiency, LOQ, accuracy, precision, and robustness

What Qualification Typically Covers

Qualification sits between development and validation. It is a fit-for-purpose confirmation that the assay performs well enough for the intended use at that stage. It typically includes:

• Precision and accuracy, where quantification is required
• Sensitivity and range estimates
• Matrix or extraction assessments, where these are expected to affect interpretation
• Fewer replicates and less extensive design than a full validation
• Documentation sufficient to support the intended decision

What Happens During Validation

Validation applies a locked, predefined protocol to formally confirm assay performance across the parameters relevant to the context of use. Depending on the assay and intended application, this may include:

• Precision and accuracy
• PCR efficiency, especially for qPCR
• Dilutional linearity and co-linearity
• Sensitivity, including LOB, LOD and LLOQ, and the full assay range where applicable
• Specificity and selectivity
• Robustness and ruggedness
• Stability, including freeze/thaw, benchtop and frozen stability
• Extraction efficiency/recovery and inhibition assessment

Extraction Efficiency and Recovery: How Much Target Do You Lose?

Every extraction process results in some degree of target loss. Nucleic acids can be lost during lysis, binding, washing, elution, transfer steps, or through degradation. The challenge is not necessarily achieving 100% recovery, but understanding how much material is lost and whether that loss is consistent.

One common approach is to add a known amount of control material – often referred to as a spike-in – before extraction. By comparing the measured amount after extraction with the amount originally added, recovery can be estimated and extraction performance monitored.

Interestingly, recovery values above 100% are sometimes observed. This does not mean that additional nucleic acid has been recovered. More often, it reflects differences between the spike-in control and the target molecule, calibration uncertainty, matrix effects, or normal analytical variation.

Recovery studies are often performed during assay development to benchmark extraction methods, identify opportunities for optimisation, and evaluate whether different extraction workflows produce comparable results. During qualification or validation, recovery measurements can be incorporated to demonstrate that the extraction workflow is sufficiently controlled and reproducible for its intended use.

Validation is often presented as a checklist of parameters and acceptance criteria. In practice, it starts much earlier, with a clear understanding of what question the assay is expected to answer and how the resulting data will be used.

Precision, accuracy, sensitivity, selectivity, robustness, stability, and recovery are ultimately just different ways of generating the evidence needed to answer that question with confidence.

Next in this series: Part 2 — Precision and Accuracy in qPCR and dPCR Assay Validation →

Frequently Asked Questions

Need Support With Assay Development or Validation?

For a broader overview of how TATAA applies these methods to biodistribution, viral shedding, and pharmacokinetics in advanced therapy programmes, see our post on precision bioanalysis for advanced therapies.

TATAA Biocenter offers GLP- and GCLP-compliant method development and validation services for qPCR and dPCR assays, from early feasibility through to regulatory submission packages. Whether you are at the development, qualification or validation stage, our team can help you design a strategy that fits your programme and data requirements.

Request a quote → or contact our team to discuss your assay needs.